{"id":11744,"date":"2025-09-17T11:40:22","date_gmt":"2025-09-17T09:40:22","guid":{"rendered":"https:\/\/www.ebma-europe.com\/the-origins-of-bigmed\/"},"modified":"2026-02-27T10:25:35","modified_gmt":"2026-02-27T09:25:35","slug":"the-origins-of-bigmed","status":"publish","type":"page","link":"https:\/\/www.ebma-europe.com\/en\/the-origins-of-bigmed\/","title":{"rendered":"The Origins of BI(G)MED"},"content":{"rendered":"\n
\n
<\/span>
\n\t
\n\t\t\n\n\t
    \n\t\t\t\t\t
  1. \n\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\tHome\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t<\/ol>\n\n\t<\/nav>\t<\/div>\n\n\n

    \n\tThe Origins of BI(G)MED<\/h1>\n\n\n\n

    In the very early 2000s, the complete sequencing of human DNA (the “Human Genome”<\/a> project) highlighted the importance of genetics in the functioning of the immune system<\/strong>. <\/p>\n\n\n\n

    Dr. Gilbert Glady, then specializing in micro-immunotherapy<\/a>, quickly perceived the full potential of these discoveries.<\/p>\n<\/div><\/div>\n<\/div>\n\n

    \n

    Major scientific breakthroughs<\/h2>\n\n\n\n
    \n
    \n

    1796<\/strong><\/p>\n\n\n\n

    \n

    Homeopathy & ultra-low doses<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Samuel Hahnemann<\/strong> <\/a>founded homeopathy, introducing the principle of infinitesimal dilutions.<\/p>\n<\/div>\n\n\n\n

    \n

    1869<\/strong><\/p>\n\n\n\n

    \n

    Discovery of DNA<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Friedrich Miescher<\/a> <\/strong>isolated a substance in cell nuclei that he named “nuclein” (later recognized as DNA).<\/p>\n<\/div>\n\n\n\n

    \n

    1893<\/strong><\/p>\n\n\n\n

    \n

    First steps toward immunotherapy<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    William B. Coley<\/strong> <\/a>demonstrated that tumors could be treated by stimulating the immune system.<\/p>\n<\/div>\n\n\n\n

    \n

    1942<\/strong><\/p>\n\n\n\n

    \n

    Discovery of epigenetics<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Conrad Hal Waddington<\/a> <\/strong>laid the foundations for the modification of the phenotype by the environment without affecting DNA.<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n

    \n
    \n
    \n

    1953<\/strong><\/p>\n\n\n\n

    \n

    Double helix structure of DNA<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    James<\/strong> Watson<\/strong><\/a> and Francis Crick<\/a><\/strong> described the structure of DNA, based on data from Rosalind Franklin.<\/p>\n<\/div>\n\n\n\n

    \n

    1975<\/strong><\/p>\n\n\n\n

    \n

    Monoclonal antibodies <\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Georges K\u00f6hler<\/a> and Cesar Milstein<\/a><\/strong> developed monoclonal antibody technology, the foundation of future immunotherapies.<\/p>\n<\/div>\n\n\n\n

    \n

    1993<\/strong><\/p>\n\n\n\n

    \n

    Discovery of microRNAs (miRNAs)<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Victor Ambros <\/a>and Gary Ruvkun<\/a><\/strong> identified the first microRNA in the nematode C. elegans<\/em>, regulating gene expression.<\/p>\n<\/div>\n\n\n\n

    \n

    1996<\/strong><\/p>\n\n\n\n

    \n

    Epigenetic mechanisms<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Recognition of histone modifications and methylation as key regulatory mechanisms.<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n

    \n
    \n
    \n

    1998<\/strong><\/p>\n\n\n\n

    \n

    RNA interference (RNAi)<\/h3>\n\n\n\n
    \"\"<\/figure>\n\n\n\n

    Andrew Fire<\/a> and Craig Mello<\/a> <\/strong>discovered that double-stranded RNA can specifically inhibit gene expression, a mechanism known as RNA interference.<\/p>\n<\/div>\n<\/div>\n\n\n\n

    \n

    2000s<\/strong><\/p>\n\n\n\n

    \n

    Research on non-coding RNAs<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Recognition that the majority of the genome transcribes non-coding RNA: lncRNA, circRNA, piRNA\u2026<\/p>\n<\/div>\n\n\n\n

    \n

    Since 2010<\/strong><\/p>\n\n\n\n

    \n

    Research on ultra-low doses<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Studies on hormesis, weak signals, water memory, nanostructures, and ultra-low-dose RNAs.<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n

    \n

    From micro-immunotherapy to BI(G)MED<\/h2>\n\n\n\n
    \n
    \n

    1983-2010<\/strong><\/p>\n\n\n\n

    \"\"<\/figure>\n\n\n\n
    \n

    Dr. Gilbert Glady<\/a> disseminated micro-immunotherapy in Europe<\/strong>, after working alongside Dr. Maurice Jenaer, a pioneer in the use of high dilutions in immunology.<\/p>\n<\/div>\n<\/div>\n\n\n\n

    \n

    2010<\/strong><\/p>\n\n\n\n

    \"\"<\/figure>\n\n\n\n
    \n

    Dr. Gilbert Glady <\/a>created Bio Immuno(G)enetic Medicine <\/strong>(BI(G)MED), integrating these discoveries to better modulate gene expression through microRNAs.<\/p>\n<\/div>\n<\/div>\n\n\n\n

    \n

    2012<\/strong><\/p>\n\n\n\n

    \"\"<\/figure>\n\n\n\n
    \n

    Dr. Gilbert Glady<\/a> created the European Bio Immuno(G)enetic Medicine Association<\/strong> EBMA <\/a>to develop and promote BI(G)MED in Europe.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n

    \n

    Thanks to the contribution of genetics and epigenetics, BI(G)MED presents itself as an innovative therapeutic method<\/strong>, capable of influencing the molecular and immune mechanisms at the heart of many pathologies.<\/p>\n\n\n\n

    Its rapid expansion in Europe<\/strong> illustrates the growing interest in these global and personalized health approaches.<\/p>\n\n\n\n

    Since the creation of BI(G)MED by Dr. Glady, hundreds of therapists have been trained<\/strong> in several countries, including France, Belgium, Switzerland, Germany, Austria, and Spain. <\/p>\n<\/div>\n\n

    \n
    \n
    \n
    <\/span>
    \n

    Learn more about BI(G)MED<\/strong><\/h2>\n\n\n\n
    \n
    BI(G)MED<\/a><\/div>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
    \n
    <\/span>
    \n

    Discover our training courses<\/strong><\/h2>\n\n\n\n
    \n
    Catalogue de formations<\/a><\/div>\n<\/div>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n

    <\/p>\n","protected":false},"excerpt":{"rendered":"

    In 2010, Dr. Glady created Bio Immuno(G)enetic Medicine (BI(G)MED), integrating these discoveries in micro-immunotherapy to better modulate gene expression through microRNAs.<\/p>\n","protected":false},"author":778,"featured_media":0,"parent":0,"menu_order":10,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-11744","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nFrom micro-immunotherapy to Bio Immuno(G)enetic Medicine | EBMA Europe<\/title>\n<meta name=\"description\" content=\"In 2010, Dr. Glady created Bio Immuno(G)enetic Medicine by integrating his discoveries in micro-immunotherapy. Discover the full historical context.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ebma-europe.com\/en\/the-origins-of-bigmed\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"From micro-immunotherapy to Bio Immuno(G)enetic Medicine | EBMA Europe\" \/>\n<meta property=\"og:description\" content=\"In 2010, Dr. Glady created Bio Immuno(G)enetic Medicine by integrating his discoveries in micro-immunotherapy. Discover the full historical context.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ebma-europe.com\/en\/the-origins-of-bigmed\/\" \/>\n<meta property=\"og:site_name\" content=\"EBMA Europe\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-27T09:25:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/01\/1796.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/the-origins-of-bigmed\\\/\",\"url\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/the-origins-of-bigmed\\\/\",\"name\":\"From micro-immunotherapy to Bio Immuno(G)enetic Medicine | EBMA Europe\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/the-origins-of-bigmed\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/the-origins-of-bigmed\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ebma-europe.com\\\/wp-inside\\\/uploads\\\/2026\\\/01\\\/1796-1024x683.png\",\"datePublished\":\"2025-09-17T09:40:22+00:00\",\"dateModified\":\"2026-02-27T09:25:35+00:00\",\"description\":\"In 2010, Dr. Glady created Bio Immuno(G)enetic Medicine by integrating his discoveries in micro-immunotherapy. Discover the full historical context.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/the-origins-of-bigmed\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/the-origins-of-bigmed\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/the-origins-of-bigmed\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.ebma-europe.com\\\/wp-inside\\\/uploads\\\/2026\\\/01\\\/1796-1024x683.png\",\"contentUrl\":\"https:\\\/\\\/www.ebma-europe.com\\\/wp-inside\\\/uploads\\\/2026\\\/01\\\/1796-1024x683.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/the-origins-of-bigmed\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/accueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Origins of BI(G)MED\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/\",\"name\":\"EBMA Europe\",\"description\":\"European Bio Immune(G)ene Medicine Association\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/#organization\"},\"alternateName\":\"EBMA\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/#organization\",\"name\":\"EBMA Europe\",\"alternateName\":\"EBMA\",\"url\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ebma-europe.com\\\/wp-inside\\\/uploads\\\/2026\\\/03\\\/enity-logo-ebma.png\",\"contentUrl\":\"https:\\\/\\\/www.ebma-europe.com\\\/wp-inside\\\/uploads\\\/2026\\\/03\\\/enity-logo-ebma.png\",\"width\":696,\"height\":696,\"caption\":\"EBMA Europe\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/fr.linkedin.com\\\/company\\\/ebma-europe\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"From micro-immunotherapy to Bio Immuno(G)enetic Medicine | EBMA Europe","description":"In 2010, Dr. Glady created Bio Immuno(G)enetic Medicine by integrating his discoveries in micro-immunotherapy. Discover the full historical context.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ebma-europe.com\/en\/the-origins-of-bigmed\/","og_locale":"en_US","og_type":"article","og_title":"From micro-immunotherapy to Bio Immuno(G)enetic Medicine | EBMA Europe","og_description":"In 2010, Dr. Glady created Bio Immuno(G)enetic Medicine by integrating his discoveries in micro-immunotherapy. Discover the full historical context.","og_url":"https:\/\/www.ebma-europe.com\/en\/the-origins-of-bigmed\/","og_site_name":"EBMA Europe","article_modified_time":"2026-02-27T09:25:35+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/01\/1796.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ebma-europe.com\/en\/the-origins-of-bigmed\/","url":"https:\/\/www.ebma-europe.com\/en\/the-origins-of-bigmed\/","name":"From micro-immunotherapy to Bio Immuno(G)enetic Medicine | EBMA Europe","isPartOf":{"@id":"https:\/\/www.ebma-europe.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ebma-europe.com\/en\/the-origins-of-bigmed\/#primaryimage"},"image":{"@id":"https:\/\/www.ebma-europe.com\/en\/the-origins-of-bigmed\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/01\/1796-1024x683.png","datePublished":"2025-09-17T09:40:22+00:00","dateModified":"2026-02-27T09:25:35+00:00","description":"In 2010, Dr. Glady created Bio Immuno(G)enetic Medicine by integrating his discoveries in micro-immunotherapy. Discover the full historical context.","breadcrumb":{"@id":"https:\/\/www.ebma-europe.com\/en\/the-origins-of-bigmed\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ebma-europe.com\/en\/the-origins-of-bigmed\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ebma-europe.com\/en\/the-origins-of-bigmed\/#primaryimage","url":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/01\/1796-1024x683.png","contentUrl":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/01\/1796-1024x683.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ebma-europe.com\/en\/the-origins-of-bigmed\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ebma-europe.com\/en\/accueil\/"},{"@type":"ListItem","position":2,"name":"The Origins of BI(G)MED"}]},{"@type":"WebSite","@id":"https:\/\/www.ebma-europe.com\/en\/#website","url":"https:\/\/www.ebma-europe.com\/en\/","name":"EBMA Europe","description":"European Bio Immune(G)ene Medicine Association","publisher":{"@id":"https:\/\/www.ebma-europe.com\/en\/#organization"},"alternateName":"EBMA","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ebma-europe.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ebma-europe.com\/en\/#organization","name":"EBMA Europe","alternateName":"EBMA","url":"https:\/\/www.ebma-europe.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ebma-europe.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/03\/enity-logo-ebma.png","contentUrl":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/03\/enity-logo-ebma.png","width":696,"height":696,"caption":"EBMA Europe"},"image":{"@id":"https:\/\/www.ebma-europe.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/fr.linkedin.com\/company\/ebma-europe"]}]}},"_links":{"self":[{"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/pages\/11744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/users\/778"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/comments?post=11744"}],"version-history":[{"count":3,"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/pages\/11744\/revisions"}],"predecessor-version":[{"id":11798,"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/pages\/11744\/revisions\/11798"}],"wp:attachment":[{"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/media?parent=11744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}